Biotech Roundup: Hellos, Goodbyes, “Cures” Delays And Trial News
Xconomy
JULY 15, 2016
After last week’s revelation of three patient deaths in its leading cancer immunotherapy trial, the FDA suspended the study. All eyes are on Holmes, who is scheduled to present data from the company’s technology at a medical conference on August 1. Sarepta’s drug is currently under an FDA review.
Let's personalize your content